What's New
2022.11.14
放射線科学基盤機構では、部局横断的な教育研究を促進する一環としてセミナーを開催しております。
今回、下記のとおり機構セミナーを開催いたします。
講演者はDept of Nuclear Medicine, Dusseldorf Universityの Prof. Dr. Frederik L. Giesel氏です。
ご参加をお待ち申し上げます。
機構セミナー「Targeted alpha therapy and theranostics in the future」
講師：Prof. Dr. Frederik L. Giesel （Dept of Nuclear Medicine, Dusseldorf University）
開催日時： ２０２２年11月25日１4：0０〜１5：0０
開催場所： ハイブリッド（放射線科学基盤機構附属ラジオアイソトープ総合センター吹田本館会議室 + Webex）
Webex： https://osaka-u.webex.com/osaka-u/j.php?MTID=m11935b22ff2548564863609601700880
ミーティング番号: 2516 229 9705
パスワード: A3Ps8JbT97x
※事前申込不要
連絡先：watabe@tracer.med.osaka-u.ac.jp (大阪大学大学院医学系研究科 渡部直史)
概要 Abstract
Nuclear Medicine is in a revolutionary era translating new innovative imaging probes and particular also theranostic applications to improve patient management and care.
Today, personlized medicine is one of the most important approach to improve patient treatment outcome and long lasting treatment effect. Nuclear medicine is a key player due to the matter that non-invasive patient phenotyping is possible to stratify treatment benefits using imaging-probes which later can be modified for further radio-pharmaceutical drug attacking on cellular level tumor cells and its micro-environment while sparing normal tissue.
Furthermore, ground-breaking translation work have supported the venue of utilizing instead of beta-emitter rather alpha-emitter to long lasting cancer treatment effects. Beta-Emitter in radiopharmaceuticals enables only single-strand-break, while alpha-emitter inducing double-strand-DNA breaks which often translate in direct cell death due to apoptosis and possible longer treatment duration. Many efforts have been made in science to introduce alpha-emitter into clinical enviroment, but often challenged by regulation, production chain and distribution channel.
This presentation will give an overview of the impact of alpha emitter in cancer, new targets and its recent development on a regional and global perspective.
